About pramipexole
=================

Pramipexole, a nonergoline aminobenzothiazole compound, was approved by the Food and Drug Administration for the treatment of [@b53-ndt-2-393] ([@b49-ndt-2-393]; [@b41-ndt-2-393]; [@b34-ndt-2-393]). Pramipexole is a full dopamine agonist with particular selectivity for D2 dopamine receptor family, and has a 5- to 7-fold higher affinity for D3 receptor subtypes than for either D2 or D4 receptors ([@b53-ndt-2-393]; [@b41-ndt-2-393]; [@b34-ndt-2-393]). It has a moderate opioid affinity, only minimal alpha2-adrenoceptor activity, but no other beta-adrenergic or serotonergic activity ([@b34-ndt-2-393]; [@b67-ndt-2-393]).

It is rapidly and well absorbed and not influenced by food. The peak levels of the drug appear in the bloodstream within 2 hours of oral administration with an absolute bioavailability of more than 90%, indicating its good absorption and little presystemic metabolism ([@b41-ndt-2-393]; [@b34-ndt-2-393]). Binding to plasma proteins is low ([@b47-ndt-2-393]).

Its elimination half-life ranges from 8 to 12 hours ([@b93-ndt-2-393]; [@b41-ndt-2-393]). Pramipexole is excreted unmetabolized largely through the kidney, with little or no interaction with other drugs eliminated by hepatic cytochrome P450 enzymes or other related metabolic pathways ([@b34-ndt-2-393]; [@b47-ndt-2-393]). It can therefore be safely used in patients with hepatic failure or in patients using multidrugs. It is a "category C" drug in pregnancy ([@b14-ndt-2-393]).

About restless legs syndrome
============================

Restless legs syndrome (RLS) was first described by Thomas Willis in the 17th century, and labeled as a psychosomatic disease, anxietas tibiarum, by Whittmack in the 19th century ([@b88-ndt-2-393]; [@b89-ndt-2-393]). The first report on RLS as a sensorimotor and sleep disorder, however, was written by [@b21-ndt-2-393] ([@b21-ndt-2-393]). RLS is characterized by leg paraesthesias--dysesthesias and motor restlessness worsening at rest and in the evening, with at least temporary relief by activity ([@b80-ndt-2-393]). The diagnosis of RLS is based on clinical criteria established by the International RLS Study Group (IRLSSG), and has recently been modified ([@b80-ndt-2-393]; [@b3-ndt-2-393]) ([Table 1](#t1-ndt-2-393){ref-type="table"}). RLS was found to be the fourth leading cause of insomnia ([@b11-ndt-2-393]) particularly at sleep onset.

The overall prevalence of RLS is approximately 10% ([@b62-ndt-2-393]) with variation between 6% and 11%, depending on the general population survey and the geographic location of the considered country. The symptoms are often progressive and tend to worsen with aging ([@b14-ndt-2-393]). The mean age of onset of RLS symptoms was found to be 27 years ([@b46-ndt-2-393]). Although most subjects are not diagnosed for many years, 38%--45% of adult RLS subjects have onset of symptoms before age 20 years ([@b46-ndt-2-393]; [@b83-ndt-2-393]; [@b61-ndt-2-393]), with 13% of patients reporting symptoms before the age of 10 ([@b46-ndt-2-393]). Familial aggregation of RLS is known to be more common in early onset of symptoms ([@b3-ndt-2-393]).

The recognition of RLS in childhood is complex. In 1832, Duchamp observed some children suffering aches and pains, termed "growing pains" ([@b18-ndt-2-393]). Walters and colleagues ([@b85-ndt-2-393]; [@b80-ndt-2-393]) and Ekbom ([@b22-ndt-2-393]), on the other hand, have stated that some of these children might actually have RLS. RLS in childhood may therefore be more common than appreciated. It is now well known that RLS may begin in childhood ([@b55-ndt-2-393], [@b56-ndt-2-393]; [@b84-ndt-2-393]). It was important to have well defined clinical criteria for the recognition of RLS in childhood. The IRLSSG proposed such criteria ([@b80-ndt-2-393]; [@b3-ndt-2-393]) (see [Table 2](#t2-ndt-2-393){ref-type="table"}), but a validation on a general population children group is needed, despite the fact that this is currently the best document on the matter.

The etiology of RLS remains unknown. It could be idiopathic, 50%--92% of which has familial occurrence with autosomal dominant mode of inheritance ([@b49-ndt-2-393]; [@b80-ndt-2-393]; [@b4-ndt-2-393]; [@b14-ndt-2-393]). Three different genetic loci, 12q, 14q13--21, and 9p (RLS-1, RLS-2, and RLS-3), have been reported with a recessive (RLS-1) and autosomal dominant (RLS-2, RLS-3) mode of inheritance, respectively ([@b15-ndt-2-393]; [@b8-ndt-2-393]; Winkelmann et al 2005). RLS can also be secondary to various conditions, including central and peripheral nervous system disorders, metabolic disturbances, pregnancy, anemia, and so forth ([@b12-ndt-2-393]; [@b30-ndt-2-393]).

The most important development in the understanding of the pathophysiology of RLS was achieved by the demonstration of dopaminergic hypofunction by [@b1-ndt-2-393], who demonstrated the relief of RLS symptoms by levodopa treatment. The marked improvement achieved with dopaminergic agonists, exacerbation of RLS symptoms with dopamine antagonists, and increased frequency of RLS in patients with PD suggests that dopamine plays a crucial role in the pathophysiology of RLS ([@b14-ndt-2-393]). In addition, imaging studies using ligands showed that dopaminergic activity in the central nervous system, particularly in the striatonigral system, is reduced in patients with RLS ([@b77-ndt-2-393]; [@b63-ndt-2-393]).

Why pramipexole in RLS
======================

The pharmacological treatment of RLS has developed greatly since [@b1-ndt-2-393] reported complete resolution of RLS symptoms with levodopa. Later studies consistently showed the beneficial effects of levodopa given with a peripheral decarboxylase inhibitor in both primary and also secondary RLS patients ([@b9-ndt-2-393]; [@b78-ndt-2-393]; [@b76-ndt-2-393]). Levodopa was the first drug of choice in RLS, as it is usually well tolerated in most patients ([@b10-ndt-2-393]; [@b32-ndt-2-393]). On the other hand, some adverse reactions have limited its use ([@b28-ndt-2-393]; [@b13-ndt-2-393]; [@b32-ndt-2-393]).

Rebound phenomenon, worsening of symptoms at the end of a dosing period leading to late-night or morning recurrence of symptoms ([@b28-ndt-2-393]; [@b23-ndt-2-393]), is seen in approximately 25% of patients on levodopa for RLS ([@b14-ndt-2-393]). It has been reported that 35% of RLS patients treated with levodopa for long periods developed morning restlessness, which resolved within 1 week upon discontinuation ([@b28-ndt-2-393]). This complication is most commonly seen when the regular-release formula of levodopa--carbidopa is used ([@b23-ndt-2-393]). This rebound restlessness may be overcome by an additional levodopa dose during daytime, but may also decrease the compliance ([@b28-ndt-2-393]; [@b50-ndt-2-393]).

Augmentation is seen in more than 80% of RLS patients with long-term use of levodopa, leading to apparent worsening of symptoms ([@b2-ndt-2-393]; [@b61-ndt-2-393]; [@b14-ndt-2-393]; [@b67-ndt-2-393]). In the augmentation phenomenon, symptoms progressively increased in severity have an earlier onset in the day involving the other parts of the body beyond the legs ([@b61-ndt-2-393]; [@b19-ndt-2-393]). If augmentation is taken to be a decrease in drug efficacy, as the dosage is increased, greater augmentation is seen. Augmentation is more common in severe RLS patients with a higher dose of medication ([@b23-ndt-2-393]).

Another complication of long-term levodopa treatment is tolerance, the need for larger doses to maintain the original effect. [@b2-ndt-2-393] showed that following about 21 months of treatment, 59% of patients with RLS needed to increase their levodopa dose. However, the increase in dosage may also be due to the development of augmentation.

Due to the abovementioned complications of levodopa, dopamine agonists, with prolonged duration of action, have become the primary treatment for RLS. It has been shown in many studies that all dopamine receptor agonists licensed for PD can also be used effectively in the treatment of RLS ([@b9-ndt-2-393]). Therefore, dopamine agonists are now being used as the first choice of treatment, especially in moderate-to-severe RLS, and in the presence of daytime symptoms or augmentation ([@b9-ndt-2-393]). In secondary RLS, the underlying condition should first be addressed, but dopaminergic drugs may also be helpful ([@b14-ndt-2-393]). However, although D2-receptor agonists of ergot derivatives, such as bromocriptine ([@b82-ndt-2-393]) and pergolide (Earley and Allen 1997), are shown to be effective in RLS, some major and frequent side-effects limit their usefulness. Some degree of augmentation with these dopaminergic agonists was also reported between 9% and 18% in different studies ([@b48-ndt-2-393]; [@b68-ndt-2-393]; [@b23-ndt-2-393]). The augmentation with pergolide, for instance, was shown to affect 15%--25% of patients ([@b19-ndt-2-393]; [@b70-ndt-2-393]). Moreover, it has also been reported that some degree of symptoms persists even after treatment with these agents.

Pramipexole, being selective for the D3 receptor and also a nonergot compound, does not have the frequently encountered problems seen with dopamine agonists of ergot derivative (see below). An initial pramipexole follow-up study in 7 RLS patients showed that none had augmentation after a mean period of 7.8 months ([@b48-ndt-2-393]). Even if these initial long-term results have not be confirmed in all cases and presence of augmentation has been shown with all dopamine agonists tried to date on RLS, pramipexole has been commonly used without problem for many months. In addition, pramipexole in the treatment of the symptoms of RLS has been shown to be very effective.

In rare cases, benzodiazepines, opioids, and anticonvulsants have also be given, particularly in cases of treatment failure with dopaminergic agents ([@b32-ndt-2-393]; [@b64-ndt-2-393]; [@b64-ndt-2-393]; [@b66-ndt-2-393]). The question of the potential role of IV infusion of iron as an intermittent treatment or supplemental treatment of RLS is currently under investigation ([@b20-ndt-2-393]).

Studies with pramipexole in adult RLS and periodic limb movements in sleep (PLMS) patients
==========================================================================================

Pramipexole in RLS and PLMS
---------------------------

### RLS and PLMS

The studies with pramipexole performed in adult patients have clearly shown that the drug is effective in the treatment of RLS in placebo-controlled, double-blind studies ([Table 3](#t3-ndt-2-393){ref-type="table"}). Compared with levodopa, which improved leg restlessness by about 40% in a blind-designed study, pramipexole improved RLS symptoms by about 80% ([@b9-ndt-2-393]; [@b30-ndt-2-393]), which suggests that pramipexole is more potent than levodopa. However, to compare two different studies with different diagnostic criteria used in selection of the population questions this statement, revealing the need for head-to-head comparative studies. Pramipexole also has a major effect on PLMS index and PLMS-related arousals when associated with RLS ([@b50-ndt-2-393]). Pramipexole has also been compared with another nonergot dopamine agonist, the drug ropinirole, which has demonstrated a similar positive effect on PLMS index. Ropinirole, with a shorter half-life, has been reported to improve sleep efficiency less ([@b64-ndt-2-393]; [@b67-ndt-2-393]). The efficacy of pramipexole on secondary RLS has also been reported in many studies, including uremic RLS in dialysis patients ([@b45-ndt-2-393]) ([Table 3](#t3-ndt-2-393){ref-type="table"}). All dopaminergic agents, including pramipexole, are effective in secondary forms of RLS--PLMS ([@b7-ndt-2-393]; [@b76-ndt-2-393]; [@b42-ndt-2-393]; [@b45-ndt-2-393]). The drug can thus be used to treat RLS and PLMS associated with underlying conditions.

Based on both short- and long-term observational and controlled studies, some also with polysomnography, the recommended dosage of pramipexole ranges normally between 0.375 and 0.75 mg/day ([@b50-ndt-2-393]). A very low initial optimal therapeutic dose of pramipexole (0.25 mg/day) was reported to have a very rapid efficacy in 66% of RLS patients ([@b14-ndt-2-393]). About 50% of the studied patients were reported to have moderate or marked improvement after the first to third administration of such dosage. This rapid action of pramipexole even at low dosages is hypothesized to indicate a more specific role of D3 receptors of the mesolimbic system in the pathophysiology of RLS ([@b75-ndt-2-393]; [@b14-ndt-2-393]).

### Sleep

Most of the sleep laboratory studies showed that there is no effect of pramipexole on total sleep time, number of awakenings, sleep continuity, or sleep efficiency ([@b50-ndt-2-393]; [@b45-ndt-2-393]). Similar results were also reported in levodopa trials in RLS patients ([@b9-ndt-2-393]; [@b35-ndt-2-393]; [@b76-ndt-2-393]). It has been found, however, that pramipexole may delay REM sleep latency and decrease total percentage of REM sleep ([@b50-ndt-2-393]). Acute administration of pramipexole, 0.25mg, has been shown to increase sleep stages NREM-1 and 2 and stage shifts, while slow-wave and REM sleep decreased significantly compared with placebo ([@b67-ndt-2-393]). The dopamine agonist pergolide has also been reported to significantly improve total sleep time (TST), total sleep period, and sleep efficiency, and also increase the number of spontaneous awakenings in stage 2 nonREM sleep, and decrease stages 3+4 with the alteration in the distribution of non REM sleep towards more light sleep ([@b87-ndt-2-393]; [@b64-ndt-2-393]) but with an improvement of subjective sleep quality. Moreover, a partial antidepressive effect of pramipexole has also been found, supporting a dopaminergic dysfunction in the pathogenesis of these two disorders ([@b67-ndt-2-393]).

Studies with pramipexole in childhood RLS and PLMS
==================================================

There are few studies on RLS in children, and fewer with pramipexole. But it is now known that RLS is much more common in children than previously assumed.

Clinical presentations in children
----------------------------------

### Growing pains

The most common misdiagnosis of childhood RLS is growing pains ([@b85-ndt-2-393]). A study of 112 children diagnosed as having growing pains showed that some children had sensation of cramps or creeping very similar to RLS ([@b81-ndt-2-393]). A polysomnographic (PSG) study in 10 children with growing pains showed they all met clinical criteria for definite RLS ([@b60-ndt-2-393]). Interestingly, the positive family history of growing pains was also more common in these children (51.0% vs 12.5% of children without growing pains) ([@b81-ndt-2-393]). In addition, 7 of 60 patients with age of onset of RLS symptoms before 20 years reported that they had the diagnosis of growing pains ([@b46-ndt-2-393]).

### Attention deficit hyperactivity disorder (ADHD)

High prevalence of RLS symptoms in children with ADHD and PLMS has also been reported ([@b55-ndt-2-393]). Many children with ADHD have RLS symptoms (eg, leg paraesthesias) due to their ADHD symptoms ([@b85-ndt-2-393]). On the other hand, some children with ADHD signs and symptoms might actually have RLS ([@b57-ndt-2-393]). In addition, many of the parents of children with ADHD and RLS--PLMS were also shown to have RLS symptoms or PLMS in some studies ([@b57-ndt-2-393]).

To explain the close relationship between ADHD and RLS--PLMS, a genetic linkage between these two disorders has been hypothesized, with the possibility that they might share a common deficit in dopaminergic pathways ([@b56-ndt-2-393]). This hypothesis is supported by well-known therapeutic response of RLS--PLMS to dopaminergic agents ([@b41-ndt-2-393]; [@b51-ndt-2-393]), as well as the evidence that ADHD, in some cases, is genetically linked to the dopaminergic system ([@b39-ndt-2-393]; [@b79-ndt-2-393]).

Iron deficiency, low serum ferritin levels ([@b37-ndt-2-393]; [@b36-ndt-2-393]), diabetes mellitus type 1 ([@b31-ndt-2-393]), and RLS-like symptoms possibly associated with streptococcal or *Mycoplasma pneumoniae* infections ([@b44-ndt-2-393]) have also been reported as etiological factors in children with secondary RLS.

### Treatment studies

Treatment of childhood RLS remains largely unexplored. There are some reports on children with ADHD and RLS--PLMS treated with carbidopa--levodopa and clonidine with moderate benefit ([@b85-ndt-2-393]; [@b60-ndt-2-393]), and clonazepam with no benefit ([@b57-ndt-2-393]; [@b85-ndt-2-393]). Another study was performed on 7 children with RLS--PLMS treated with prescription dopaminergic drugs, either levodopa or pergolide. The children had shown no benefit from prior stimulant therapy, but demonstrated long-term improvement in RLS, PLMS, and the associated arousals, along with objective and subjective improvements in ADHD ([@b4-ndt-2-393]). However, the effect of improvement in ADHD symptoms on the amelioration of RLS--PLMS cannot be excluded. Finally, a study of PLMS performed in children indicated association of the polysomnographic findings of PLM with many etiologies, including association with RLS and with ADHD ([@b43-ndt-2-393])

There are only 2 studies with pramipexole usage in childhood RLS--PLMS, both of which were performed at the Stanford sleep center. The first was carried out in prepubertal children with sleep disorders. Six children with PLMS and 2 with RLS and PLMS were given pramipexole, and 5 out of these 6 had a complete disappearance of their PLMS demonstrated by follow-up polysomnography and were able to well tolerate the drug ([@b43-ndt-2-393]). These 5 children have been followed now for a minimum of 3 years. One of the 2 children with PLM and RLS has developed augmentation after close to 3 years of pramipexole intake. Another had drug intake terminated by family concerned about long-term intake of a dopamine agonist, and 3 children are still taking the dopaminergic agent without side-effects. The 6th child developed side-effect very soon after initiation of treatment and was switched to levodopa, and after 2 years to ropinirole. Parents stopped usage of any drugs after 6 years of treatment again because of concern about the effect of long-term drug intake. The other study, of 84 children (5 with sleep terrors and 79 with both sleep terrors and sleepwalking) with a control group of 36 healthy children, revealed that 2 sleepwalkers had accompanying RLS. These 2 children had disrupted sleep during the first sleep cycle. The nocturnal sleep disruption associated with the RLS--PLM was hypothesized to possibly be a factor in the occurrence of sleepwalking events. Each child was treated for RLS with pramipexole. Follow-up recording showed absence of PLMS and no report of symptoms of RLS. There was simultaneous observation of complete absence of confusional arousals at long-term follow-up with no parasomnia reported since treatment ([@b29-ndt-2-393]). These 2 children have been followed for either 2 or 3 years. RLS symptoms and parasomnia have not been reported at recent follow-up but increase in drug intake has been necessary in both cases due to reports of reappearance of mild symptoms of RLS 7 and 9 months ago, respectively. All children studied (n=7) were all started with the recommended lowest effective daily dosage, ie, 0.25mg. The first week, each child was started with 0.125mg taken at evening meal. When absence of any side-effect at the end of the first week was observed, each child's daily dosage was increased to 0.25mg. The rationale to select the same dosage as in adults was that dopamine agonists have been used in children with abnormal movements at higher dosage; and child metabolism, overall, is faster than adult metabolism. The current maximum daily dosage administered to a child is 0.50mg at evening meal. Observation of side-effects led to immediate interruption of drug administration, and all children had a general pediatric examination every 6 months and a simple blood test evaluation every year.

Side-effects of pramipexole in patients with RLS
================================================

Augmentation--rebound phenomena
-------------------------------

As mentioned, augmentation and rebound phenomena are the main problems that limit the usefulness of levodopa. It was in the first trials on pramipexole that augmentation or rebound were reported to be absent with the continunation of benefits of pramipexole therapy ([@b48-ndt-2-393]). [@b48-ndt-2-393] had followed 7 RLS patients taking pramipexole with a mean daily dose 0.125mg for a mean of 7.8 months without augmentation. On the other hand, subsequent studies have shown that augmentation with pramipexole, although rare, could be seen. [@b23-ndt-2-393] found that only 9 of 102 RLS patients (9%) had augmentation after at least 6 months of pramipexole treatment. [@b68-ndt-2-393] reported augmentation with pramipexole occurring in 18% of 50 RLS patients who had failed previous dopaminergic treatment. However, nearly two-thirds of those patients had developed augmentation with either levodopa or pergolide. An observational study reported augmentation in 8.5% of patients during long-term treatment with pramipexole ([@b24-ndt-2-393]), very close to the percentage (8.3%) found in another study ([@b23-ndt-2-393]). However, a very high rate of subjects developing augmentation, 32%, was reported in another study ([@b90-ndt-2-393]), similar to the ratio reported for augmentation seen with pergolide ([@b69-ndt-2-393]), but still lower than the 50% reported in patients treated with levodopa ([@b19-ndt-2-393]). The authors who reported the need to increase the initial therapeutic dose of pramipexole in 32% of their cases mentioned that the increase could also be due to some degree of tolerance to the drug or increasing severity of RLS, in addition to RLS augmentation ([@b69-ndt-2-393]). Factors such as natural progression of RLS, fluctuations in underlying disease severity, or different study designs in terms of inclusion criteria for patients might be responsible for the discrepancy noted in the different reports ([@b90-ndt-2-393]). But in this specific study ([@b90-ndt-2-393]) anatomical extension of symptoms was found in only 5% (3/59) of patients, and this percentage involved only patients who presented augmentation or tolerance.

The investigations on the possible risk factors associated with the appearance of augmentation revealed that it was not related to medication dosage or severity of RLS before the onset of pramipexole treatment ([@b23-ndt-2-393]). Two factors most likely to affect augmentation were reported as: (a) pretreatment with levodopa, and (b) secondary RLS compared with idiopathic RLS ([@b23-ndt-2-393]; [@b90-ndt-2-393]). Patients with a positive family history and normal electromyographic examination results were also reported as predictors for augmentation ([@b52-ndt-2-393]).

The risk of observing augmentation was found to be highest soon after starting treatment, mostly within the first 4 months of treatment ([@b23-ndt-2-393]). The shortest time to augmentation was reported to be 2 months after initiation of treatment ([@b69-ndt-2-393]). In the first year of treatment, about 20% of patients experienced augmentation, and in the second year, 10% of patients. After 2.5 years, it has been said that no previously unaffected patient developed augmentation ([@b69-ndt-2-393]).

A comparison of carbidopa--levodopa or pergolide augmentation with pramipexole augmentation revealed that it was significantly less common with pramipexole ([@b69-ndt-2-393]). It is reasonable that augmentation would be less frequent and less severe with pramipexole than with levodopa. For a similar reason, morning rebound and nocturnal penetrations of RLS symptoms were rare. In general, augmentation with pramipexole appears to be less severe, and is easily managed by earlier medication dosing ([@b69-ndt-2-393]; [@b90-ndt-2-393]).

Sleep attacks
-------------

The excessive daytime somnolence in the form of sudden sleep attacks that are involved even in motor vehicle accidents was first reported by [@b27-ndt-2-393], with the use of pramipexole and ropinirole in patients with PD. Since then, there have been reports of sudden, irresistible sleep episodes as an adverse effect with dopaminergic agents ([@b6-ndt-2-393]) in PD patients. However, this adverse effect was not encountered in RLS patients treated with pramipexole ([@b25-ndt-2-393]; [@b71-ndt-2-393]).

[@b5-ndt-2-393], [@b6-ndt-2-393] reported daytime somnolence in 4 out of 16 patients taking pramipexole for RLS. In another study, excessive daytime sleepiness was noted in 5% of patients ([@b69-ndt-2-393]). None of these patients had sleep attacks. However, in this study, 3 patients with excessive daytime sleepiness with no sleep attacks felt the need to discontinue the medication ([@b69-ndt-2-393]). [@b73-ndt-2-393] also found that 1 of 24 patients described sleepiness with no sleep attacks. The lower risk of sleepiness with pramipexole, especially while driving, could be related to the differences in dose and timing of medication compared with PD patients ([@b74-ndt-2-393]; [@b69-ndt-2-393]). This opinion has been emphasized in one study by comparing doses, as RLS patients are mostly treated with a mean dose of 0.37 mg/day ([@b71-ndt-2-393]), while PD patients with sleep attacks had been given pramipexole at a mean dose of 2.9 mg/day ([@b25-ndt-2-393]).

Other side-effects
------------------

The other more common but less serious side-effects of pramipexole noted in the drug trials for RLS relief include nausea or dyspepsia, constipation, anorexia, insomnia--alertness, sleepiness or stiffness during the day, fatigue, headache, dizziness, fluid retention--edema, and tachycardia ([@b86-ndt-2-393]; [@b14-ndt-2-393]; [@b67-ndt-2-393]; [@b33-ndt-2-393]). But these side-effects are reported as usually affecting a low number of subjects and usually not causing the drug trial to be interrupted. Although about 40% of patients were reported to have side-effects with the medication ([@b69-ndt-2-393]) ([Table 4](#t4-ndt-2-393){ref-type="table"}), they occurred at initiation, and were only mild, tolerable, and transient, disappearing within 1 week ([@b50-ndt-2-393]; [@b86-ndt-2-393]; [@b69-ndt-2-393]). In addition, one must emphasize that studies that are not placebo-controlled might overestimate the adverse reactions. Pramipexole is believed to have fewer adverse effects than pergolide. Side-effects were reported in 60%--68% of patients taking pergolide for RLS ([@b70-ndt-2-393], [@b68-ndt-2-393]; [@b73-ndt-2-393]).

It must be emphasized that [@b43-ndt-2-393] report a child treated for PLMS with pramipexole who had treatment terminated soon after beginning of drug intake due to increased daytime sleepiness and behavior changes that included "blunted affect" and personality change with "strangeness" as verbalized by parents. These effects were seen at 0.25 mg/day. Interruption of treatment led to return to normal behavior within 3 days.

Overall potential side-effects of pramipexole
=============================================

Side-effects of pramipexole have been well published previously for its usage in PD, a pathology not considered here. Patients with either early or advanced PD were enrolled in clinical trials. Patients with early disease had no concomitant levodopa therapy, while patients with advanced PD received a combined treatment of levodopa along with pramipexole.

In double-blind, placebo-controlled trials of patients with early PD, the most commonly observed adverse events were reported as nausea, dizziness, somnolence, constipation, asthenia, and hallucinations ([@b53-ndt-2-393]; [@b59-ndt-2-393]; [@b92-ndt-2-393]) ([Table 5](#t5-ndt-2-393){ref-type="table"}). Approximately 12% of 388 patients with early PD discontinued treatment due to adverse events, compared with 11% of 235 patients taking placebo. The most common adverse events associated with discontinuation were found to be hallucinations, dizziness, somnolence, extrapyramidal syndrome, headache, confusion, and nausea. It must be remembered that not only the dosage but also the neurological lesions are very different between RLS and PD.

An interesting side-effect of pramipexole, pathological gambling in PD patients, was recently reported in 2 studies ([@b17-ndt-2-393]; [@b16-ndt-2-393]). Out of a total of 1884 PD patients, 529 were treated with pramipexole, 421 with ropinirole, and 331 with pergolide ([@b17-ndt-2-393]). Seven men and 2 women were found to have symptoms of obsessive or excessive gambling. Of these 9 subjects, 8 were on pramipexole (mean dosage 4.3 mg/day, range 2--8 mg/day) and 1 was on pergolide (4.5 mg/day) at the onset of symptoms. In the second paper ([@b16-ndt-2-393]), pramipexole was the agonist in 9 of 11 PD patients who developed pathological gambling within 3 months of treatment or more, with demonstrated resolving of the gambling problem after discontinuation of the drug. A survey very recently performed on 32 of our RLS patients who took pramipexole on a daily basis for over a year did not elicit any indication of obsessive behavior change since the start of medication, but considering the very large number of patients with PD necessary to demonstrate presence of this side-effect, our sample is most likely too small.

In double-blind, placebo-controlled trials with pramipexole and concomitant levodopa in patients with advanced PD, the most common adverse events were orthostatic hypotension, dyskinesia, extrapyramidal syndrome, insomnia, dizziness, hallucinations, accidental injury, dream abnormalities, confusion, constipation, asthenia, somnolence, dystonia, gait abnormality, hypertonia, dry mouth, amnesia, and urinary frequency ([@b40-ndt-2-393]; [@b38-ndt-2-393]; [@b58-ndt-2-393]) ([Table 6](#t6-ndt-2-393){ref-type="table"}). Approximately 12% of 260 patients discontinued treatment due to adverse events compared with 16% of 264 patients receiving placebo. The events most commonly causing discontinuation were noted as hallucinations, dyskinesia, extrapyramidal syndrome, dizziness, and confusion orthostatic hypotension.

We thanks Nickisa Hodgson for her editing of the manuscript.

**Disclosures**The authors have no conflicts of interest and nothing to disclose.

###### 

Clinical features of the restless legs syndrome (RLS) in adults[a](#tfn1-ndt-2-393){ref-type="table-fn"} ([@b80-ndt-2-393]; [@b3-ndt-2-393])

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Diagnostic featuresAn urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legsThe urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sittingThe urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretchingThe urge to move or unpleasant sensations are worse in the evening or night than during the day or occur only in the evening or night
  Supportive clinical featuresPositive family historyPositive response to dopaminergic therapyPresence of periodic limb movements (during wakefulness or sleep)
  Associated features of RLSVariable clinical course, but typically chronic and often progressivePhysical examination normal in idiopathic--familial formsSleep disturbance is a common complaint in more affected patients
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Diagnostic features are those mandatory for a definite clinical diagnosis. Supportive clinical features are those which may increase the probability of a diagnosis in doubtful cases, such as is common in children. Associated features are typical, but do not contribute to diagnosis.

###### 

Diagnostic criteria for childhood restless legs syndrome(RLS) ([@b80-ndt-2-393]; [@b3-ndt-2-393])

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Definite childhood RLSThe child meets all 4 essential adult criteria for RLS (see [Table 1](#t1-ndt-2-393){ref-type="table"}), andThe child relates a description in his or her own words that is consistent with leg discomfort
  or
  The child meets all 4 essential adult criteria for RLS (see [Table 1](#t1-ndt-2-393){ref-type="table"}), andTwo of 3 following supportive criteria are present: Sleep disturbance for ageA biological parent or sibling has definite RLSThe child has a polysomnographically documented periodic limb movement index of 5 or more per hour of sleep.
  Probable childhood RLSThe child meets all essential adult criteria for RLS, except criterion \#4 (the urge to move or sensations are worse in the evening or at night than during the day), andThe child has a biological parent or sibling with definite RLS
  or
  The child is observed to have behavior manifestations of lower extremity discomfort when sitting or lying, accompanied by motor movement of the affected limbs, the discomfort has characteristics of adult criteria 2, 3, and 4 (ie, is worse during rest and inactivity, relieved by movement, and worse during the evening and at night), andThe child has a biological parent or sibling with definite RLS.
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Studies with pramipexole in adult RLS patients

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                            Trial/study design                                                Measures                            Patients                                                                                    Duration                                    Dosage                                                                             Primary outcomes                                                                            Secondary outcomes
  -------------------------------- ----------------------------------------------------------------- ----------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------- ---------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------
  [@b41-ndt-2-393]                 Open-label                                                        Visual analog scale                 15 out of 16 patients (94%) completed study\                                                2--3 mo                                     Mean dose 0.3 mg/d                                                                 Suppresses RLS symptoms                                                                     Suppresses daytime augmentation
                                                                                                                                         Symptomatic RLS Treatment-resistant RLS                                                                                                                                                                                                                                                                                

  [@b5-ndt-2-393]                  Open-label clinical                                               Short IRLSSG                        23 moderate to severe resistant RLS patients (primary and secondary) (19 completed trial)   1--5 mo                                     Single dose of 0.125 mg (nighttime symptoms); 0.125 mg bid/tid (daily symptoms)\   Significant improvement                                                                     
                                                                                                                                                                                                                                                                                 Mean dose of 0.35+0.15 mg/d (Dallas); 1.6+1.0 mg/d (Houston)                                                                                                                   

  [@b50-ndt-2-393]                 Double-blind, randomized, crossover with placebo control          RLS severity home questionnaire\    10 out of 11 subjects completed trial                                                       4 wk of trials with 2-wk washout period     0.375 mg/d increased up to 1.5 mg/d vs placebo                                     Effective in treating sensory and motor symptoms of RLS\                                    No improvement in sleep continuity, efficiency, sleep latency, TST, number of awakenings
                                                                                                     Polysomnogram                                                                                                                                                                                                                                                  0.375--0.75 mg completely eradicated RLS in 9 patients\                                     
                                                                                                                                                                                                                                                                                                                                                                    Decrease in PLMS by 98%                                                                     

  [@b26-ndt-2-393]                 Observational                                                     IRLSSG                              4 resistant RLS patients (primary and secondary)                                            Mean of 8.9 mo (1.5--12 mo)                 Average dose of 0.75 mg/d                                                          Control of symptoms without any significant side-effects or need of medication adjustment   Difficulty initiating or maintaining sleep unimproved

  [@b48-ndt-2-393]                 Follow-up for long-term efficacy                                  Home questionnaire                  7 RLS patients                                                                              Mean follow-up duration of 7.8 mo           0.25 mg/d increased to optimal dose                                                Efficacy throughout 24 h with a single dose at bedtime                                      Long-lasting beneficial effect on RLS symptoms

  [@b67-ndt-2-393]                 Single-blind, placebo-controlled crossover                        IRLSSG\                             11 patients with primary RLS\                                                               After night (acute)\                        Acute after night dose of 0.27 mg/d\                                               Total scores of the IRLSSG improved\                                                        Improved sleep efficiency and quality compared to placebo\
                                                                                                     Polysomnography\                    10 patients completed 4-week follow-up                                                      4-wk follow-up                              4 wk trial mean dose of 0.28±0.1 mg/d                                              Significant decrease in PLMs/h                                                              Significant decrease in PSQI--QOL\
                                                                                                     Psychometry\                                                                                                                                                                                                                                                                                                                                               Daytime sleepiness and depression improved
                                                                                                     Zung Depression and Anxiety Scale                                                                                                                                                                                                                                                                                                                          

  Quality of Life Index\                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Pittsburgh SleepQuality Index\                                                                                                                                                                                                                                                                                                                                                                                                                                
  Epworth Sleepiness Scale                                                                                                                                                                                                                                                                                                                                                                                                                                      

  [@b69-ndt-2-393]                 Retrospective review                                                                                  60 consecutive RLS patients                                                                 Mean of 27.2 mo                             Median initial dose of 0.38 mg/d                                                   Completely effective in 2 out of 3 patients; ineffective in 7%                              

  [@b42-ndt-2-393]                 Open-label without placebo-control group                          Suggested Immobilization Test\      24 never treated primary (20) and secondary RLS patients                                    30--60 d (mean 39 d) after optimal dosage   0.25--0.50 mg/d                                                                    Significantlyimproved the subjective RLS symptoms and IRLSSGRS scores                       Significant decrease in mean movement index
                                                                                                     IRLSSG                                                                                                                                                                                                                                                                                                                                                     

  [@b52-ndt-2-393]                 Follow-up                                                         Subjective report by patients       52 out of 83 patients with nonuremic RLS                                                    39.2+20.9 mo (7--101 mo)                    0.79+0.55 mg/d                                                                     Effectively treat RLS                                                                       

  [@b72-ndt-2-393]                 Short-term open label                                             IRLSSG\                             17 patients with severe primary RLS\                                                        4 wk                                        0.125--0.75 mg/d (a mean of 0.3+0.2 mg)                                            Rapid complete or pronounced relief of RLS symptoms\                                        Significantly improved sleep by reduction in sleep onset latency, increase in TST, increase in sleep efficiency
                                                                                                     Polysomnography                     (13 patients resistant to levodopa)                                                                                                                                                                                        Worsening of RLS symptoms under levodopa recovered\                                         
                                                                                                                                                                                                                                                                                                                                                                    Significant improvement in PLM index, PLMA index                                            

  [@b45-ndt-2-393]                 Follow-up                                                         IRLSSG\                             10 uremic RLS patients                                                                      1 mo                                        Mean dose of 0.25 mg/d (0.125--0.5 mg/d)                                           Decrease in mean severityscale score\                                                       No changes in sleep latency, TST, number of awakenings, or sleep efficiency
                                                                                                     Polysomnography (8 patients)                                                                                                                                                                                                                                   Decrease in PLMW index                                                                      

  [@b54-ndt-2-393]                 Large randomized double-blind, placebo-controlled, dose-finding                                       109 patients with RLS                                                                       NS                                          0.5--0.75 mg/d vs placebo                                                          Significant decrease in severity of symptoms                                                
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** d, day; h, hour; IRLSSG, International RLS Study Group questionnaire; mo, months; NS, not significant; PLMS, periodic leg movement during sleep; PLMA, periodic leg movements sleep arousal index; PLMW, periodic leg movements while awake; PSQI--QOL, Pittsburgh Sleep Quality Index -quality of life; RLS, restless legs syndrome; TST, total sleep time; wk, weeks.

###### 

Side-effects in rest legs syndrome (RLS) patients treated by pramipexole ([@b69-ndt-2-393])

  Side-effect                    Number of patients affected (%)
  ------------------------------ ---------------------------------
  Insomnia                       8 (13)
  Nausea or dyspepsia            7 (12)
  Postural lightheadedness       6 (10)
  Excessive daytime sleepiness   3 (5)
  Nasal stuffiness               3 (5)
  Limb numbness or pain          2 (3)
  Headache                       1 (2)
  Anxiety                        1 (2)
  Depression                     1 (2)
  Peripheral edema               1 (2)
  Constipation                   1 (2)
  Palpitations                   1 (2)

###### 

Treatment-emergent adverse events in early Parkinson's disease (combined data from: [@b53-ndt-2-393]; [@b59-ndt-2-393]; [@b92-ndt-2-393])

  Adverse events           Pramipexole (n=388)   Placebo (n=235)
  ------------------------ --------------------- -----------------
  Asthenia                 14                    12
  General edema            5                     3
  Malaise                  2                     1
  Reaction unevaluable     2                     1
  Fever                    1                     0
  Nausea                   28                    18
  Constipation             14                    6
  Anorexia                 4                     2
  Dysphagia                2                     0
  Peripheral edema         5                     4
  Decreased weight         2                     0
  Dizziness                25                    24
  Somnolence               22                    9
  Insomnia                 17                    12
  Hallucinations           9                     3
  Confusion                4                     1
  Amnesia                  4                     2
  Hypesthesia              3                     1
  Dystonia                 2                     1
  Akathisia                2                     0
  Thinking abnormalities   2                     0
  Decreased libido         1                     0
  Myoclonus                1                     0
  Vision abnormalities     3                     0
  Impotence                2                     1

###### 

Treatment-emergent adverse events in Advanced Parkinson's Disease ([@b40-ndt-2-393]; [@b38-ndt-2-393]; [@b58-ndt-2-393]).

  Adverse events                Pramipexole (n=260)   Placebo (n=264)
  ----------------------------- --------------------- -----------------
  Accidental injury             17                    15
  Asthenia                      10                    8
  General edema                 4                     3
  Chest pain                    3                     2
  Malaise                       3                     2
  Postural hypotension          53                    48
  Constipation                  10                    9
  Dry-mouth                     7                     3
  Peripheral edema              2                     1
  Increased creatinin PK        1                     0
  Arthritis                     3                     1
  Twitching                     2                     0
  Bursitis                      2                     0
  Myasthenia                    1                     0
  Dyskinesia                    47                    31
  Extrapyramidal syndrome       28                    26
  Insomnia                      27                    22
  Dizziness                     26                    25
  Hallucinations                17                    4
  Dream abnormalities           11                    10
  Confusion                     10                    7
  Somnolence                    9                     6
  Dystonia                      8                     7
  Gait abnormalities            7                     5
  Hypertonia                    7                     6
  Amnesia                       6                     4
  Akathisia                     3                     2
  Thinking abnormalities        3                     2
  Paranoid reaction             2                     0
  Delusions                     1                     0
  Sleep disorders               1                     0
  Dyspnea                       4                     3
  Rhinitis                      3                     1
  Pneumonia                     2                     0
  Skin disorders                2                     1
  Accommodation abnormalities   4                     2
  Vision abnormalities          3                     1
  Diplopia                      1                     0
  Urinary frequency             6                     3
  Urinary tract infection       4                     3
  Urinary incontinence          2                     1
